Cited by 184Angiogenesis and VEGF in CancerCancer Cells and MetastasisExtracellular vesicles in disease

Identification and Clinical Significance of Circulating Endothelial Progenitor Cells in Human Non-small Cell Lung Cancer

Dome, Balazs, Timar, Jozsef, Dobos, Judit, Meszaros, Livia, Raso, Erzsebet, Paku, Sandor, Kenessey, Istvan, Ostoros, Gyula +4 more·2006·Cancer Research

Abstract

Until recently, it was generally accepted that vascularization of tumors arises exclusively from endothelial sprouting. Whether circulating bone marrow-derived endothelial progenitor cells (EPC) participate in the progression of non-small cell lung cancer (NSCLC) has not yet been evaluated. EPCs labeled with CD34, CD133, and vascular endothelial growth factor receptor-2 (VEGFR2) antibodies were counted by flow cytometry in the peripheral blood of 53 NSCLC patients. Furthermore, by means of a quantitative reverse transcription-PCR approach, we measured VEGFR2, CD133, CD34, and VE-cadherin mRNA in the peripheral blood samples of the same patient population. EPCs in tumor samples were identified by confocal microscopy using CD31, CD34, CD133, and VEGFR2 antibodies. Although immunofluorescent labeling of microvessels made clear that incorporation of EPCs is a rare phenomenon in NSCLC tissue (9 of 22 cases), circulating EPC levels before therapeutic intervention were increased in NSCLC patients (P < 0.002, versus healthy controls), and high pretreatment circulating EPC numbers correlated with poor overall survival (P < 0.001). Furthermore, in the subgroup of responders to treatment, the posttreatment EPC numbers in the peripheral blood were significantly lower compared with nonresponding patients. Interestingly, pretreatment mRNA levels of CD133, VE-cadherin, and CD34 were not significantly increased in NSCLC patients, whereas VEGFR2 expression was increased by 80-fold. Moreover, posttreatment VEGFR2 mRNA level in the peripheral blood was significantly higher in the subgroup of nonresponding patients when compared with posttreatment level of patients responding to antitumor therapy. Circulating levels of bone marrow-derived EPCs are significantly increased in NSCLC patients and correlate with clinical behavior.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-05-4654

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The contribution of vasculogenesis to the vascularization of tumor tissue is minimal in humans.

    “However, the contribution of vasculogenesis to the vascularization of tumor tissue is minimal in humans [21].”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Dome, B., Timar, J., Dobos, J., Meszaros, L., Raso, E., Paku, S., Kenessey, I., Ostoros, G., Magyar, M., Ladanyi, A., Bogos, K., & Tovari, J.
Affiliations
  • 1Tumor Biology and Departments of
  • National Institute of Oncology (HU)
  • 3Tumor Progression, National Institute of Oncology; and
  • 4Department of Molecular Pathology, Joint Research Organization of the Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary
  • 2Thoracic Oncology, National Koranyi Institute of Pulmonology;
Venue
Cancer Research
Published
2006-07-15
Volume
66
Issue
14
Pages
7341-7347
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2139739577
Cited by
184
References
39
Citations by year
2025: 1 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 4 · 2020: 2 · 2019: 6 · 2018: 4 · 2017: 7 · 2016: 7 · 2015: 5 · 2014: 12 · 2013: 14 · 2012: 18
FWCI
8.24
Type
journal article
Language
en
Open access
closed
Locations
  • Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
endothelial progenitor cells, non-small cell lung cancer, VEGFR2, CD133, CD34, VE-cadherin, tumor vascularization, bone marrow-derived cells, treatment response, overall survival, tumor microvasculature
MeSH terms
AC133 Antigen, Cadherin 5, Carcinoma, Non-Small-Cell Lung, Female, Flow Cytometry, Glycoproteins, Humans, Lung Neoplasms, Male, Middle Aged, Neovascularization, Pathologic, Peptides, RNA, Messenger, Stem Cells, Biomarkers, Tumor, Antigens, CD, Cadherins, Antigens, CD34, Reverse Transcriptase Polymerase Chain Reaction, Vascular Endothelial Growth Factor Receptor-2, Endothelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review